Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY 3,825.00
-15.00 (-0.39%)
Nov 13, 2026, 3:30 PM JST
Kaken Pharmaceutical Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 144,846 | 156,775 | 176,794 | 130,992 | 138,463 | 147,114 | |
Market Cap Growth | 4.79% | -11.32% | 34.97% | -5.40% | -5.88% | -11.44% |
Enterprise Value | 89,182 | 114,787 | 100,891 | 68,690 | 72,334 | 84,580 |
Last Close Price | 3825.00 | 4039.54 | 4169.44 | 3075.03 | 3149.72 | 3186.34 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 15.83 | 73.12 | 12.68 | 16.32 | 25.45 | 15.41 |
Forward PE | 24.21 | 77.77 | 22.01 | 19.39 | 13.57 | 13.10 |
PS Ratio | 1.68 | 2.04 | 1.88 | 1.82 | 1.90 | 1.94 |
PB Ratio | 0.95 | 1.06 | 1.16 | 0.91 | 1.01 | 1.06 |
P/TBV Ratio | 1.12 | 1.27 | 1.33 | 0.96 | 1.07 | 1.14 |
P/FCF Ratio | 19.23 | - | 6.90 | 182.95 | 19.06 | 14.21 |
P/OCF Ratio | 12.96 | - | 5.94 | 50.83 | 14.96 | 11.03 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.03 | 1.49 | 1.07 | 0.95 | 0.99 | 1.11 |
EV/EBITDA Ratio | 6.88 | 47.32 | 4.28 | 5.60 | 6.85 | 4.33 |
EV/EBIT Ratio | 9.84 | - | 4.80 | 7.22 | 9.04 | 4.96 |
EV/FCF Ratio | 11.84 | - | 3.94 | 95.94 | 9.96 | 8.17 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Debt / EBITDA Ratio | 0.30 | 1.59 | 0.16 | 0.31 | 0.36 | 0.20 |
Debt / FCF Ratio | 0.51 | - | 0.15 | 5.38 | 0.53 | 0.37 |
Net Debt / Equity Ratio | -0.36 | -0.32 | -0.43 | -0.43 | -0.51 | -0.51 |
Net Debt / EBITDA Ratio | -4.29 | -19.31 | -2.81 | -5.01 | -6.66 | -3.62 |
Net Debt / FCF Ratio | -7.39 | 3.33 | -2.58 | -85.86 | -9.69 | -6.84 |
Asset Turnover | 0.47 | 0.42 | 0.52 | 0.43 | 0.44 | 0.46 |
Inventory Turnover | 1.89 | 1.93 | 1.96 | 2.05 | 2.19 | 2.28 |
Quick Ratio | 3.23 | 3.53 | 3.01 | 4.68 | 4.49 | 4.98 |
Current Ratio | 4.17 | 4.52 | 3.67 | 5.62 | 5.27 | 5.81 |
Return on Equity (ROE) | 6.08% | 1.43% | 9.41% | 5.72% | 3.95% | 6.96% |
Return on Assets (ROA) | 3.10% | -0.30% | 7.26% | 3.52% | 3.02% | 6.49% |
Return on Invested Capital (ROIC) | 7.31% | -0.89% | 17.90% | 10.48% | 9.53% | 18.01% |
Return on Capital Employed (ROCE) | 5.50% | -0.60% | 13.10% | 6.20% | 5.50% | 11.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 6.32% | 1.37% | 7.89% | 6.13% | 3.93% | 6.49% |
FCF Yield | 5.20% | -8.98% | 14.50% | 0.55% | 5.25% | 7.03% |
Dividend Yield | 4.97% | 4.59% | 3.26% | 4.34% | 4.06% | 3.86% |
Payout Ratio | 78.88% | 303.08% | 51.62% | 70.49% | 103.84% | 59.84% |
Buyback Yield / Dilution | 0.88% | 0.66% | -1.13% | -0.44% | 1.07% | 1.59% |
Total Shareholder Return | 5.84% | 5.25% | 2.13% | 3.89% | 5.13% | 5.44% |